Search Results - "Yndestad, S."

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer by Eikesdal, H.P., Yndestad, S., Elzawahry, A., Llop-Guevara, A., Gilje, B., Blix, E.S., Espelid, H., Lundgren, S., Geisler, J., Vagstad, G., Venizelos, A., Minsaas, L., Leirvaag, B., Gudlaugsson, E.G., Vintermyr, O.K., Aase, H.S., Aas, T., Balmaña, J., Serra, V., Janssen, E.A.M., Knappskog, S., Lønning, P.E.

“…The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi…”
Get full text

184PD - Neoadjuvant olaparib monotherapy in primary triple negative breast cancer by Eikesdal, H.P., Yndestad, S., Blix, E.S., Lundgren, S., Vagstad, G., Espelid, H., Gilje, B., Janssen, E.A., Geisler, J., Aas, T., Aase, H., Knappskog, S., Lønning, P.E.

“…Neoadjuvant treatment of triple negative breast cancer (TNBC) in general implies different chemotherapy regimens administered in sequence. PARP inhibitors like…”
Get full text

Neoadjuvant olaparib monotherapy in primary triple negative breast cancer by Eikesdal, H.P., Yndestad, S., Blix, E.S., Lundgren, S., Vagstad, G., Espelid, H., Gilje, B., Janssen, E.A., Geisler, J., Aas, T., Aase, H., Knappskog, S., Lønning, P.E.

Get full text

184PDNeoadjuvant olaparib monotherapy in primary triple negative breast cancer by Eikesdal, H P, Yndestad, S, Blix, E S, Lundgren, S, Vagstad, G, Espelid, H, Gilje, B, Janssen, E A, Geisler, J, Aas, T, Aase, H, Knappskog, S, Lønning, P E

“…Abstract Background Neoadjuvant treatment of triple negative breast cancer (TNBC) in general implies different chemotherapy regimens administered in sequence…”
Get full text